Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

Iovance Biotherapeutics Appoints Jean-Marc

Bellemin as Chief Financial Officer

SAN CARLOS, Calif., Dec. 14, 2020 -- Iovance

Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies,

today announced the appointment of Jean-Marc Bellemin as Chief Financial Officer, effective today. Mr. Bellemin brings 27 years

of industry experience in finance, including public companies.

"I am very pleased to welcome Jean-Marc to Iovance during

such an important time for the Company," stated Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.

"Jean-Marc has extensive experience as a CFO in public biopharma companies with commercial products and with a global footprint,

as well as an understanding of cell therapy products. His qualifications are well aligned with Iovance's goals and directions."

Mr. Bellemin has 27 years of progressive international experience

in finance, business leadership and operations management within start-up and global multi-billion-dollar organizations. Most recently

he served as Executive Vice President and Chief Financial Officer of Gritstone Oncology, where he led the overall financial strategy

and multiple private and public financings, including an initial public offering and first equity follow-on financing. Previously

Mr. Bellemin held roles of increasing responsibility at Actelion Pharmaceuticals, from 2002 until the 2017 acquisition by Johnson

& Johnson. As Senior Vice President and Chief Financial Officer, Head of Finance and Market Access at Actelion Pharmaceuticals

US Inc., he provided strategic leadership, operations, and financial management. Mr. Bellemin was actively involved in the launch

of six drugs within five years, including three blockbusters' drugs, helping drive Actelion US to $1.8 billion in

"I am very excited to join Iovance and help lead the important

transition toward bringing TIL to patients in a commercial setting," said Mr. Bellemin. "I believe TIL cell therapy

is a true platform with the potential to address many thousands of cancer patients in multiple indications throughout the world.

I look forward to offering my expertise in global finance and commercial operations to help create value for patients and physicians,

as well as Iovance shareholders."

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment

of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune

cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process,

and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed

dosing in the pivotal study in patients with metastatic melanoma and cervical. In addition, the company's TIL therapy is

being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck

and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood

lymphocyte (PBL) therapy is open to enrollment. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking

statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us,"

or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All

such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements

and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing,

we may, in some cases, use terms such as "predicts," "believes," "potential," "continue,"

"estimates," "anticipates," "expects," "plans," "intends," "forecast,"

"guidance," "outlook," "may," "could," "might," "will,"

"should" or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking

statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience

and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update

or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are

not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our

control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different

from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments

and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors"

in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly

Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties

inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully

develop, submit, obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval

of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates

for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from

ongoing clinical trials may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials;

the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory

agency input; the new version of the protocol which further defines the patient population to include more advanced patients in

our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct

additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities;

the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation

of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement

by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility

may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing

processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances

and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments,

not within our control.

Iovance Biotherapeutics, Inc:

Sara Pellegrino, IRC

Vice President, Investor Relations & Public Relations

650-260-7120 ext. 264

Chad Rubin (investors)